Table 2 Clinical baseline parameters of patient cohort

Age (years) at VIT-initiation, median (IQR)

47 (20)

14 (6)

48 (19)

Sex

 Male

580

55.1

45

63.4

535

54.5

.17

 Female

472

44.9

26

36.6

446

45.5

Diagnosis: IgE-mediated allergy to

 Bee venom

167

15.9

23

32.4

144

14.7

<.001

 Vespula venom

856

81.4

47

66.2

809

82.5

 Bee and Vespula venom

29

2.8

1

1.4

28

2.9

IgE to causative insect (kU/L), median (IQR)

 Bee venom

8.7 (22.2)

15.3 (36.6)

8.0 (21.0)

.013

 Vespula venom

4.8 (11.4)

6.7 (15.5)

4.8 (11.2)

.37

Baseline serum tryptase concentration

 Availability^b

628

59.7

33

46.5

595

60.7

 Median (µg/L) (IQR)

4.4 (3.2)

3.5 (1.9)

4.4 (3.2)

.014

Severity of index sting-induced anaphylaxis

 Grade I (mild)

138

13.1

5

7.0

133

13.6

 Grade II (moderate)

647

61.5

59

83.1

588

59.9

 Grade III (severe)

267

25.4

7

9.9

260

26.5

.001

Cardiovascular comorbidities

289

27.5

0

0

289

29.5

<.001

Concurrent cardiovascular medication

 Any

277

26.3

0

0

277

28.2

<.001

 ACE-inhibitor

131

12.5

0

0

131

13.4

<.001

 Beta-blocker

59

5.6

0

0

59

6

.028

Latency (months) from index sting to VIT, median (IQR)

7 (7)

8 (6)

7 (7.5)

.19